Genzyme issues Award of Excellence to Shanghai ChemPartner

ShangPharma Corporation (NYSE:SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that its wholly-owned contract research subsidiary, Shanghai ChemPartner, received an Award of Excellence from Genzyme.

“We are honored to receive this award and appreciate Genzyme's recognition of the efforts and dedication of our talented team of scientists. This award reflects the value and capabilities of ChemPartner's service to our partners.”

The award recognizes ChemPartner's outstanding performance and valued contributions to the Genzyme-ChemPartner collaboration over the past almost three years. The collaboration has contributed to Genzyme's success in a number of early discovery programs. ChemPartner has consistently met and exceeded Genzyme's expectations by providing high-quality science, efficient project management and effective communication.

Dr. Jim Burns, SVP of Drug and Biomaterial Discovery and Development at Genzyme, commented, "It is our long-term strategy to partner with the best CROs in supporting our drug R&D programs. In so doing, our internal drug R&D resources can be used more effectively across multiple programs. ChemPartner has proven its capabilities and effectiveness during almost three years of working with us and has become our preferred choice for a chemistry contract research organization."

Michael Hui, founder and CEO of ShangPharma, added, "We are honored to receive this award and appreciate Genzyme's recognition of the efforts and dedication of our talented team of scientists. This award reflects the value and capabilities of ChemPartner's service to our partners."

Source: ShangPharma